WO1998006864A3 - Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat - Google Patents

Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat Download PDF

Info

Publication number
WO1998006864A3
WO1998006864A3 PCT/US1997/015270 US9715270W WO9806864A3 WO 1998006864 A3 WO1998006864 A3 WO 1998006864A3 US 9715270 W US9715270 W US 9715270W WO 9806864 A3 WO9806864 A3 WO 9806864A3
Authority
WO
WIPO (PCT)
Prior art keywords
heat
gene expression
shock protein
spatial
combination
Prior art date
Application number
PCT/US1997/015270
Other languages
French (fr)
Other versions
WO1998006864A2 (en
Inventor
Chrit Moonen
Original Assignee
Chrit Moonen
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chrit Moonen, Us Gov Health & Human Serv filed Critical Chrit Moonen
Priority to JP10510126A priority Critical patent/JP2001501458A/en
Priority to AU42416/97A priority patent/AU732872C/en
Priority to EP97940696A priority patent/EP0922110B1/en
Priority to DE69738640T priority patent/DE69738640T2/en
Priority to CA002263706A priority patent/CA2263706A1/en
Publication of WO1998006864A2 publication Critical patent/WO1998006864A2/en
Publication of WO1998006864A3 publication Critical patent/WO1998006864A3/en
Priority to US10/096,549 priority patent/US7186698B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides methods for using local heat to control gene expression. The heat shock protein (hsp) gene promoter is recombined with a selected therapeutic gene and expressed in selected cells. Local controlled heating is used to activate the hsp promoter, for example by using focused ultrasound controlled by MRI.
PCT/US1997/015270 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat WO1998006864A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP10510126A JP2001501458A (en) 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a combination of heat shock protein promoter and local heating
AU42416/97A AU732872C (en) 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
EP97940696A EP0922110B1 (en) 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
DE69738640T DE69738640T2 (en) 1996-08-15 1997-08-14 SPATIAL AND TEMPORARY CONTROL OF GENE EXPRESSION BY MEANS OF A HEAT SHOCK PROMOTER IN COMBINATION WITH LOCAL HEAT
CA002263706A CA2263706A1 (en) 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
US10/096,549 US7186698B2 (en) 1996-08-15 2002-03-11 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2421396P 1996-08-15 1996-08-15
US60/024,213 1996-08-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09242244 A-371-Of-International 1997-08-14
US10/096,549 Continuation US7186698B2 (en) 1996-08-15 2002-03-11 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Publications (2)

Publication Number Publication Date
WO1998006864A2 WO1998006864A2 (en) 1998-02-19
WO1998006864A3 true WO1998006864A3 (en) 1998-05-14

Family

ID=21819426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015270 WO1998006864A2 (en) 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Country Status (8)

Country Link
US (2) US7186698B2 (en)
EP (1) EP0922110B1 (en)
JP (2) JP2001501458A (en)
AT (1) ATE392481T1 (en)
AU (1) AU732872C (en)
CA (1) CA2263706A1 (en)
DE (1) DE69738640T2 (en)
WO (1) WO1998006864A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342596B1 (en) 1998-05-05 2002-01-29 Hsf Pharmaceuticals S.A. Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
EP1109582A4 (en) * 1998-08-18 2004-11-03 Res Dev Foundation Methods to enhance and confine expression of genes
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6684097B1 (en) 1999-04-22 2004-01-27 University Of Miami Intraoperative monitoring of temperature-induced tissue changes with a high-resolution digital x-ray system during thermotherapy
WO2001025462A1 (en) * 1999-10-01 2001-04-12 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
US6953659B2 (en) * 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of nucleic acids
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
EP1420643B1 (en) 2001-07-10 2008-04-23 Sonogene, LLC Enhancement of transfection of dna into the liver
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
WO2004111246A1 (en) * 2003-06-19 2004-12-23 Peter Bromley Protein production system
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
AT500838B1 (en) * 2004-04-20 2007-11-15 Veterinaermedizinische Uni Wie MULTIPLE HSE
US20090022785A1 (en) * 2005-05-03 2009-01-22 Veterinarmedizinische Universitat Wien Permeable Capsules
NZ565631A (en) 2005-08-03 2011-01-28 Adelaide Res & Innovation Pty Polysaccharide synthases
US7774057B2 (en) * 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
US20070190028A1 (en) * 2006-02-13 2007-08-16 Jihong Qu Method and apparatus for heat or electromagnetic control of gene expression
US7871406B2 (en) * 2006-08-04 2011-01-18 INTIO, Inc. Methods for planning and performing thermal ablation
US8335554B2 (en) * 2006-08-22 2012-12-18 Koninklijke Philips Electronics N.V. Method and device for obtaining information about a mammalian body
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
EP2370583B1 (en) 2008-11-28 2020-07-15 Empresa Brasileira de Pesquisa Agropecuária - EMBRAPA Use of at(n) insertions in promoter elements for controlling the expression levels of coding sequences in plants
US20110127254A1 (en) * 2009-11-30 2011-06-02 Cypress Technology Llc Electric Heating Systems and Associated Methods
US9848950B2 (en) 2012-04-27 2017-12-26 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized disease treatment by ablation
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
EP3094347A4 (en) * 2014-01-17 2018-04-04 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents
US11504427B2 (en) * 2016-11-22 2022-11-22 The Regents Of The University Of California Acoustic and ultrasound-based mechanogenetics and thermogenetics for immunotherapy
US11318330B2 (en) * 2018-09-26 2022-05-03 General Electric Company Neuromodulation techniques
WO2020172515A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
WO2021050658A1 (en) * 2019-09-10 2021-03-18 The Regents Of The University Of California Ultrasound-based thermogenetics for immunotherapy
US11176717B2 (en) * 2019-09-26 2021-11-16 Siemens Healthcare Gmbh Guiding protocol development for magnetic resonance thermometry
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
EP4136228A1 (en) * 2020-04-15 2023-02-22 California Institute of Technology Thermal control of t-cell immunotherapy through molecular and physical actuation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004727A1 (en) * 1986-02-06 1987-08-13 The General Hospital Corporation Inducible heat shock and amplification system
WO1987005935A1 (en) * 1986-04-04 1987-10-08 Battelle Memorial Institute At Columbus, Ohio Gene Methods and compositions for expression of competent eukaryotic gene products
EP0263908A1 (en) * 1986-10-15 1988-04-20 Battelle Memorial Institute Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo
EP0299127A1 (en) * 1987-07-16 1989-01-18 IntraCel Corporation A method for the expression of recombinant genes under stimulation from an inducively expressed activator protein
WO1990001543A1 (en) * 1988-07-29 1990-02-22 Intracel Corporation Method for the genetic expression of heterologous proteins by cells transfected in vivo
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1995000178A1 (en) * 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy
WO1995003418A2 (en) * 1993-07-22 1995-02-02 Beth Israel Hospital Association Recombinant bcg vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO172595C (en) 1983-02-07 1993-08-11 Battelle Memorial Institute PROCEDURE AND EXPRESSION PLASMID FOR THE PREPARATION OF HEMAGGLUTININ UNDER CONTROL OF DROSOPHILA HSP PROMOTER
AU604214B2 (en) 1985-07-31 1990-12-13 Battelle Memorial Institute An improved heat-shock control method and system for the production of competent eukaryotic gene products
ZA892518B (en) 1988-04-08 1989-12-27 Intracel Corp Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
US5521084A (en) * 1992-11-10 1996-05-28 Biostar, Inc. Bovine heat shock promoter and uses thereof
US5979454A (en) * 1995-05-15 1999-11-09 The Regents Of The University Of California Method and apparatus for causing rapid and deep spatially selective coagulation during thermally mediated therapeutic procedures
US5490840A (en) * 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004727A1 (en) * 1986-02-06 1987-08-13 The General Hospital Corporation Inducible heat shock and amplification system
WO1987005935A1 (en) * 1986-04-04 1987-10-08 Battelle Memorial Institute At Columbus, Ohio Gene Methods and compositions for expression of competent eukaryotic gene products
EP0263908A1 (en) * 1986-10-15 1988-04-20 Battelle Memorial Institute Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo
EP0299127A1 (en) * 1987-07-16 1989-01-18 IntraCel Corporation A method for the expression of recombinant genes under stimulation from an inducively expressed activator protein
WO1990001543A1 (en) * 1988-07-29 1990-02-22 Intracel Corporation Method for the genetic expression of heterologous proteins by cells transfected in vivo
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1995000178A1 (en) * 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy
WO1995003418A2 (en) * 1993-07-22 1995-02-02 Beth Israel Hospital Association Recombinant bcg vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DREANO M ET AL: "ANTIBODY FORMATION AGAINST HEAT-INDUCED GENE PRODUCTS EXPRESSED IN ANIMALS", BIO/TECHNOLOGY, vol. 6, no. 11, November 1988 (1988-11-01), pages 1340 - 1343, XP000029286 *

Also Published As

Publication number Publication date
US20020165191A1 (en) 2002-11-07
AU732872C (en) 2002-02-21
DE69738640D1 (en) 2008-05-29
EP0922110B1 (en) 2008-04-16
WO1998006864A2 (en) 1998-02-19
AU4241697A (en) 1998-03-06
ATE392481T1 (en) 2008-05-15
CA2263706A1 (en) 1998-02-19
DE69738640T2 (en) 2009-07-16
AU732872B2 (en) 2001-05-03
JP2001501458A (en) 2001-02-06
US20050059623A1 (en) 2005-03-17
EP0922110A2 (en) 1999-06-16
US7186698B2 (en) 2007-03-06
JP2008291043A (en) 2008-12-04

Similar Documents

Publication Publication Date Title
AU4241697A (en) Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
WO1998002546A3 (en) Dna immunization against chlamydia infection
MY110664A (en) Protein c derivatives
MX9705039A (en) Programmed cell death genes and proteins.
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
AU2795292A (en) Synthetic dna sequence having enhanced insecticidal activity in maize
ATE384798T1 (en) POLYPEPTIDES WITH PHYTASE ACTIVITY AND NUCLEIC ACIDS ENCODING THEM
IL175698A0 (en) Phosphodiesterase 8a
AU3307999A (en) Phosphodiesterase 10
AU3802595A (en) Tripeptidyl aminopeptidase
CA2097698A1 (en) Human dopamine d4 receptor and its uses
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO1994003602A3 (en) A novel human dopamine receptor and its uses
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
IL141984A0 (en) Akt nucleic acids, polypeptides, and uses thereof
AU5810498A (en) Method and constructs for inhibiting protein expression in bacteria
CA2226889A1 (en) An expression control sequence for general and effective expression of genes in plants
IL129922A0 (en) Tissue specific expression of retinoblastoma protein
AU3118095A (en) Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme
WO1999030736A3 (en) Methods to treat undesirable immune responses
WO1999009182A3 (en) Rab proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2263706

Country of ref document: CA

Ref country code: CA

Ref document number: 2263706

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 510126

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997940696

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997940696

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09242244

Country of ref document: US